Last reviewed · How we verify
NCT06823063
Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD
Phase 1 trial testing MSC in CTD-ILD in 18 participants. Not yet recruiting.
30 October 2026
Quick facts
| Lead sponsor | Shanghai IxCell Biotechnology Co., LTD |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 April 2025 |
| Primary completion | 30 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- MSC — full drug profile →
Conditions studied
- CTD-ILD — all drugs for CTD-ILD →
Sponsor
Shanghai IxCell Biotechnology Co., LTD — full company profile →
Who can join
Adults 18 to 80, any sex, with CTD-ILD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and tolerability of IxCell hUC-MSC-P in the treatment of patients with connective tissue disease-related interstitial lung disease. To evaluate the efficacy, pharmacokinetics and immunogenicity of IxCell hUC-MSC-P in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.
Zhang Y, Yu X, Li P, Ouyang Y, et al · · 2026 · PMID 41952158 · DOI 10.1186/s12916-026-04833-9
Verify or expand the search:
- PubMed search for NCT06823063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MSC
Trials testing the same drug.
- NCT06813157 — Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia · NA · recruiting
- NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
- NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
- NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown
- NCT03552848 — Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection · NA · unknown
Other recruiting trials for CTD-ILD
Currently open trials in the same condition.
- NCT06644144 — P4O2 ILD Extension · recruiting
Other Shanghai IxCell Biotechnology Co., LTD trials
Trials by the same sponsor.
- NCT07197606 — Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke · Phase 2 · not yet recruiting
- NCT06716281 — Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis · Phase 3 · recruiting
- NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06823063 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai IxCell Biotechnology Co., LTD
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06823063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing